Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity

Blood

Volumn 115, Issue 22, 2010, Pages 4393-4402

  Mössner, Ekkehard ^a   Brünker, Peter ^a   Moser, Samuel ^a   Püntener, Ursula ^a   Schmidt, Carla ^a   Herter, Sylvia ^a   Grau, Roger ^a   Gerdes, Christian ^a   Nopora, Adam ^a   Van Puijenbroek, Erwin ^a   Ferrara, Claudia ^a   Sondermann, Peter ^a   Jäger, Christiane ^a   Strein, Pamela ^b   Fertig, Georg ^b   Friess, Thomas ^b   Schüll, Christine ^b   Bauer, Sabine ^b   Dal Porto, Joseph ^c   Del Nagro, Christopher ^c   Dabbagh, Karim ^c   Dyer, Martin J S ^d   Poppema, Sibrand ^e   Klein, Christian ^a   Umaña, Pablo ^a   more..

^a GlycArt Biotechnology AG   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c Roche Glycart   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; GA 101; RITUXIMAB; UNCLASSIFIED DRUG; AFUTUZUMAB; CD20 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EFFECTOR CELL; FEMALE; HUMAN; LYMPH NODE; LYMPHOID TISSUE; LYMPHOMA; MACACA; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLEEN; TUMOR REGRESSION; XENOGRAFT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B CELL LYMPHOMA; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE DEPLETION; METHODOLOGY; MOUSE MUTANT; NONHODGKIN LYMPHOMA; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MACACA FASCICULARIS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN ENGINEERING; RECEPTORS, IGG; TRANSPLANTATION, HETEROLOGOUS;

EID: 77951561987     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-225979     Document Type: Article

References (40)

1. Tilly H, Zelenetz A. Treatment of follicular lymphoma: current status. Leuk Lymphoma. 2008; 49(suppl 1):7-17.
2. Cvetković RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2006;66(6):791-820.
3. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10-25.
4. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
5. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837.
6. Chan HT, Hughes D, French RR, et al. CD20- induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100-insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489.
7. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti- CD20 reagents. Blood. 2004;103(7):2738-2743.
8. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/ recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009;27(20): 3346-3353.
9. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(9):2652-2661.
10. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495.
11. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443-446.
13. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2): 435-445.
14. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non- Hodgkin lymphomas. Blood. 2004;104(6):1793-1800.
15. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371.
16. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108(8):2648-2654.
17. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008; 68(20):8384-8392.
18. Brunker P, Sondermann P, Umana P. Glycoengineered therapeutic antibodies. In: Little M, ed. Recombinant Antibodies for Immunotherapy. New York, NY: Cambridge University Press; 2009:144-156.
19. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng. 2006; 93(5):851-861.
20. Umana P, Brunker P, Ferrara C, Suter T, Puntener U, Moessner E. Antigen binding molecules with increased Fc receptor binding affinity and effector function. International Patent Application 2005;WO 2005/044859 A2.
21. Umana P, Jean-Mairet J, Bailey JE, Bailey MS. Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. U.S. Patent 2009; 7,517,670 B2.
22. Poppema S, Visser L. Biotest Bull. 1987;3:131-139.
23. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323-327.
24. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006;108(6):1975-1978.
25. Stanfield RL, Zemla A, Wilson IA, Rupp B. Antibody elbow angles are influenced by their light chain class. J Mol Biol. 2006;357(5):1566-1574.
26. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052.
27. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107(2):176-182.
28. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15-24.
29. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. The carbohydrate at FcgammaRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 2006;281(8):5032-5036.
30. + malignant disease Blood. 2008;112:Abstract 234.
31. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111(3):1456-1463.
32. Beers SA, French RR, Chan CH, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection [published online ahead of print March 16, 2010]. Blood. doi:10.1182/blood-2010-01-263533.
33. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758.
34. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947.
35. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26(11):1789-1796.
36. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27(7):1122-1129.
37. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002;8(8):801-807.
38. Barbier S, Chatre L, Bras M, et al. Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton. Haematologica. 2009;94(4): 507-517.
39. Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569-2577.
40. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol. 2007;7(12):964-974.